BRIEF—Sun Pharma buys Japanese dermatology business

India’s Sun Pharma has agreed to pay $1 million for Japanese drugmaker Pola Pharma.

The group is aiming to boost its global reach in dermatology. Pola Pharma is focused on developing and selling both branded and generic products in this therapeutic area, and has annual revenues of over $100 million.

Sun Pharma executive VP Kirti Ganorkar said: “Pola Pharma is a leading dermatology company and it will help us to launch our speciality and generic dermatology products in the Japanese market in future.”

“We also get access to local manufacturing capability enabling us to serve the Japanese pharmaceutical market more effectively.”